Prospective observational cohort study of bevacizumab combined with paclitaxel as the first-or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)

被引：0
|
作者：
Kondo, N. [1 ,11 ]
Yamamoto, Y. [2 ]
Yamashiro, H. [3 ]
Kashiwaba, M. [4 ]
Nakamura, R. [5 ]
Takahashi, M. [6 ]
Toh, U. [7 ]
Tsugawa, K. [8 ]
Narui, K. [9 ]
Tamaki, K. [10 ]
Yoshinami, T.
Ohtani, S. [12 ]
Kai, Y. [13 ]
Takano, T. [14 ]
Yanagita, Y. [15 ]
Morita, S. [16 ]
Toi, M. [17 ]
Ohno, S. [18 ]
机构：
[1] Nagoya City Univ Hosp, Dept Breast Surg, Nagoya, Aichi, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan
[3] Tenri Hosp, Dept Breast Surg, Nara, Japan
[4] Iwate Med Univ, Dept Surg, Morioka, Iwate, Japan
[5] Chiba Canc Ctr, Dept Breast Surg, 666-2 Nitonacho, Chiba 2608717, Japan
[6] NHO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
[7] Kurume Univ Hosp, Dept Surg, Kurume, Fukuoka, Japan
[8] St Marianna Univ, Sch Med Hosp, Div Breast & Endocrine Surg, Dept Surg, Kawasaki, Kanagawa, Japan
[9] Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Yokohama, Kanagawa 232, Japan
[10] Nahanishi Clin Okinawa, Dept Breast Surg, Naha, Japan
[11] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Clin Oncol, Osaka, Japan
[12] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg, Hiroshima, Japan
[13] Ueo Breast Canc Hosp, Dept Surg, Oita, Japan
[14] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan
[15] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ota, Japan
[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[17] Kyoto Univ, Grad Sch Med, Breast Surg, Kyoto, Japan
[18] Canc Inst Hosp JFCR, Ctr Breast Oncol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [1] Prospective observational cohort study of bevacizumab combined with paclitaxel as the first-or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)
    Kashiwaba, M.
    Yamamoto, Y.
    Yamashiro, H.
    Kondo, N.
    Nakamura, R.
    Takahashi, M.
    Toh, U.
    Tsugawa, K.
    Narui, K.
    Tamaki, K.
    Yoshinami, T.
    Ohtani, S.
    Kai, Y.
    Takano, T.
    Yanagita, Y.
    Morita, S.
    Toi, M.
    Ohno, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S100 - S100
  • [2] Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study
    Yamamoto, Yutaka
    Yamashiro, Hiroyasu
    Toh, Uhi
    Kondo, Naoto
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Takahashi, Masato
    Tsugawa, Koichiro
    Ishikawa, Takashi
    Nakayama, Takahiro
    Ohtani, Shoichiro
    Takano, Toshimi
    Fujisawa, Tomomi
    Toyama, Tatsuya
    Kawaguchi, Hidetoshi
    Mashino, Kojiro
    Tanino, Yuichi
    Morita, Satoshi
    Toi, Masakazu
    Ohno, Shinji
    BREAST CANCER, 2021, 28 (01) : 145 - 160
  • [3] Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study
    Yutaka Yamamoto
    Hiroyasu Yamashiro
    Uhi Toh
    Naoto Kondo
    Rikiya Nakamura
    Masahiro Kashiwaba
    Masato Takahashi
    Koichiro Tsugawa
    Takashi Ishikawa
    Takahiro Nakayama
    Shoichiro Ohtani
    Toshimi Takano
    Tomomi Fujisawa
    Tatsuya Toyama
    Hidetoshi Kawaguchi
    Kojiro Mashino
    Yuichi Tanino
    Satoshi Morita
    Masakazu Toi
    Shinji Ohno
    Breast Cancer, 2021, 28 (1) : 145 - 160
  • [4] A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer
    Qin, Shukui
    Deng, Yanhong
    Bi, Feng
    Liu, Tian Shu
    Liu, Yunpeng
    Zhang, Suzhan
    Xu, Jianming
    Shu Yongqian
    Xu, Nong
    Wu, Changping
    Wang, Xin
    Zhong, Haijun
    Feng, Jifeng
    He, Yulong
    Yang, Jianwei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Capecitabine plus paclitaxel as first-or second-line therapy: a multicenter phase II study in metastatic breast cancer.
    Meza, LA
    Amin, B
    Hill, T
    Chen, YM
    Petralia, SA
    Gradishar, WJ
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 271 - 271
  • [6] Anlotinib or bevacizumab combined with chemotherapy for the second-line HER-2 negative metastatic breast cancer: A retrospective cohort study
    Xiang, J. Y.
    Liu, J.
    Sun, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S381 - S381
  • [7] Efficacy and safety of first-line bevacizumab combined with paclitaxel in 220 patients with metastatic breast cancer: The Hungarian AVAREG observational study
    Dank, Magdolna
    Budi, Laszlo
    Landherr, Laszlo
    Piko, Bela
    Mangel, Laszlo
    Erfan, Jozsef
    Cseh, Jozsef
    Ruzsa, Agnes
    Nagy, Andras
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A phase I/II study of capecitabine (X) combined with oral vinorelbine (V) as first or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC)
    Delcambre, Corinne
    Veyret, Corinne
    Levy, Christelle
    Bourgeois, Hugues
    Allouache, Djellila
    Deblet, Marc
    Grellard, Jean-Michel
    Leconte, Alexandra
    Delozier, Thierry
    ANNALS OF ONCOLOGY, 2004, 15 : 42 - 42
  • [9] A phase I/II study of capecitabine (X) combined with oral vinorelbine (V) as first or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC).
    Delcambre, C
    Bourgeois, H
    Veyret, C
    Levy, C
    Switsers, O
    Allouache, D
    Grellard, JM
    Leconte, A
    Delozier, T
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S68 - S69
  • [10] A Phase I/II study of capecitabine (X) combined with oral vinorelbine IN) as first- or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC)
    Delcambre, C.
    Veyret, C.
    Levy, C.
    Switsers, O.
    Allouache, D.
    Raban, N.
    Grellard, J. M.
    Leconte, A.
    Delozier, T.
    EJC SUPPLEMENTS, 2005, 3 (02): : 118 - 118
12345